Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant Delta ureC hly(+) Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis, (vol 77, pg 630, 2009)

Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant Delta ureC hly(+) Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis, (vol 77, pg 630, 2009)

Bibliographic Details
Main Authors:	Tchilian, E, Desel, C, Forbes, E, Bandermann, S, Sander, C, Hill, A, Mcshane, H, Kaufmann, S
Format:	Journal article
Published:	2011

Similar Items

Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
by: Tchilian, E, et al.
Published: (2009)

Erratum: Immunogenicity and protective efficacy of prime-boost regimens with recombinant δureC hly+ Mycobacterium bovis BCG and modified Vaccinia virus Ankara expressing M. tuberculosis antigen 85A against murine tuberculosis
by: Tchilian, E, et al.
Published: (2011)

Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis, (vol 77, pg 3371, 2009)
by: Vordermeier, H, et al.
Published: (2011)

Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs.
by: Williams, A, et al.
Published: (2005)

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
by: Vordermeier, H, et al.
Published: (2009)

Erratum: Viral booster vaccines improve mycobacterium bovis BCG-induced protection against bovine tuberculosis
by: Vordermeier, H, et al.
Published: (2011)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
by: Pathan, A, et al.
Published: (2007)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
by: Pathan, A, et al.
Published: (2007)

Proteoliposomes from mycobacterium bovis BCG and mycobacterium smegmatis as new vaccine candidates against tuberculosis
by: Kadir, Ramlah
Published: (2016)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
by: McShane, H, et al.
Published: (2004)

Molecular identification of Proteus mirabilis, Vibrio species leading to CRISPR-Cas9 modification of tcpA and UreC genes causing cholera and UTI
by: Muhammad Naveed, et al.
Published: (2024-04-01)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
by: Rosario, M, et al.
Published: (2010)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
by: Mcshane, H, et al.
Published: (2001)

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
by: Stylianou, E, et al.
Published: (2015)

New tuberculosis vaccines can diminish as well as enhance BCG induced protection: Results from a murine model
by: Sander, C, et al.
Published: (2006)

Vaccination against tuberculosis: how can we better BCG?
by: Pitt, J, et al.
Published: (2013)

Vaccination against tuberculosis: How can we better BCG?
by: Pitt, J, et al.
Published: (2013)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
by: Goonetilleke, N, et al.
Published: (2003)

Histopathologic differences in granulomas of Mycobacterium bovis bacille Calmette Guérin (BCG) vaccinated and non-vaccinated cattle with bovine tuberculosis
by: C. Kanipe, et al.
Published: (2022-11-01)

Increasing the Vaccine Potential of Live M. bovis BCG by Coadministration with Plasmid DNA Encoding a Tuberculosis Prototype Antigen
by: Nicolas Bruffaerts, et al.
Published: (2014-03-01)

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.
by: Scriba, T, et al.
Published: (2010)

Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.
by: Rosario, M, et al.
Published: (2010)

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
by: Satti, I, et al.
Published: (2024)

Superinfection with SARS-CoV-2 Has Deleterious Effects on Mycobacterium bovis BCG Immunity and Promotes Dissemination of Mycobacterium tuberculosis
by: Rachel E. Hildebrand, et al.
Published: (2022-10-01)

Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (vol 17, pg 1066, 2010)
by: de Cassan, S, et al.
Published: (2011)

Miliary Tuberculosis Due to BCG Immunotherapy
by: Bilgehan AYGEN, et al.
Published: (1996-03-01)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.
by: de Cassan, S, et al.
Published: (2010)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
Published: (2011-01-01)

A case of disseminated M. bovis bacillus Calmette-Guérin (BCG) disease after one month of BCG bladder infusion therapy and analysis of 77 cases of suspected BCG infection in Japan, 2017–2022
by: Masashi Nishimura, et al.
Published: (2023-01-01)

Dissecting the <i>Mycobacterium bovis</i> BCG Response to Macrophage Infection to Help Prioritize Targets for Anti-Tuberculosis Drug and Vaccine Discovery
by: Jamie Medley, et al.
Published: (2022-01-01)

Clinical development of Modified Vaccinia virus Ankara vaccines
by: Gilbert, S
Published: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines.
by: Gilbert, S
Published: (2013)

Fighting Tuberculosis: In Search of a BCG Replacement
by: Nonna I. Nadolinskaia, et al.
Published: (2022-12-01)

Tuberculosis patients co-infected with Mycobacterium bovis and Mycobacterium tuberculosis in an urban area of Brazil
by: Marcio Roberto Silva, et al.
Published: (2013-05-01)

Tuberculosis patients co-infected with Mycobacterium bovis and Mycobacterium tuberculosis in an urban area of Brazil
by: Marcio Roberto Silva, et al.
Published: (2013-05-01)

Development of a primate model for tuberculosis vaccine research: IFN-gamma responses induced by BCG vaccination and M-tuberculosis infection in macaques
by: Dowall, S, et al.
Published: (2007)

Effect of BCG Vaccination on Childhood Tuberculosis in a Region with High Prevalence of Tuberculosis
by: L. N. Motanova, et al.
Published: (2022-07-01)

A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin.
by: Minassian, A, et al.
Published: (2012)

A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guérin
by: Minassian, A, et al.
Published: (2012)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis.
by: Poyntz, H, et al.
Published: (2014)